Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2026)

Amneal Pharmaceuticals' Operating Expenses history runs 10 years deep, the most recent figure standing at $182.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 14.79% year-over-year to $182.4 million in Q1 2026; TTM through Mar 2026 was $740.7 million, a 9.73% increase from a year earlier, with the FY2025 full-year figure at $717.2 million, up 7.13% from the prior year.
• Operating Expenses eased to $182.4 million in Q1 2026 per AMRX's latest filing, from $183.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $201.3 million in Q3 2025 and bottomed at $141.3 million in Q1 2023.
• The 5-year median for Operating Expenses is $155.2 million (2023), against an average of $162.4 million.
• Across the five-year window, Operating Expenses retreated 8.28% in 2022 and climbed 18.2% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $143.5 million in 2022, then advanced by 8.19% to $155.2 million in 2023, then increased by 18.2% to $183.4 million in 2024, then rose by 0.16% to $183.7 million in 2025, then declined by 0.74% to $182.4 million in 2026.
• Per Business Quant, the three latest AMRX Operating Expenses figures stand at $182.4 million (Q1 2026), $183.7 million (Q4 2025), and $201.3 million (Q3 2025).